Sotera Health Co. Q3 2024 Earnings Report
Sotera Health Co. (NASDAQ: SHC), a leading provider of sterilization and lab testing services, reported an 8.5% increase in total revenues year-over-year, reaching $285 million in the third quarter of 2024. The company also saw a 9% rise in adjusted EBITDA to $146 million. Adjusted earnings per share (EPS) improved to $0.17, up from $0.16 in the same quarter the previous year.
CEO Michael Petras highlighted growth across the company's segments, with Nordion and Nelson Labs experiencing significant revenue increases. The company reaffirmed its full-year revenue and adjusted EBITDA growth outlook of 4% to 6%.
Key Takeaways
- Total revenues: $285 million, an 8.5% increase YOY.
- Adjusted EBITDA: Increased by 9% to $146 million, adjusted EPS: improved to $0.17.
- Sterigenics segment: 4.3% revenue growth; Nordion increased by 28%.
- Nelson Labs: Revenues grew by 7%, core lab testing volumes improved.
- 2024 outlook: Revenue and adjusted EBITDA growth projected at 4% to 6%.
- Capital expenditures for 2024: projected between $175 million and $185 million.
- Investor Day: Scheduled for November 20, 2024, in New York City.
Company Outlook
Sotera Health maintains a positive outlook for 2024. They expect a fully diluted share count of 283-285 million shares, with peak capital expenditures anticipated in 2025, followed by decreases in 2026 and 2027.
Bearish Highlights
- Nordion's year-over-year revenue might decline, despite Q3 sequential growth.
- Pricing power for Sterigenics has diminished due to market conditions and rising labor costs.
Bullish Highlights
- Strong segment margins in Nelson Labs and continued growth in the pharma sector testing and sterilization services.
Misses
- Challenges in expert advisory services acknowledged, despite being important for FDA submissions.
- Capital expenditures affected by shifts in timing for cobalt development projects.
Q&A Highlights
- Focus on strategic shifts in capacity rather than significant growth over the next decade.
- Continued discussions with the EPA regarding NESHAP compliance, with no major rule changes expected.
- Approximately $150 million allocated to the EO upgrade program, with $30 million spent in the current year.
In summary, Sotera Health's third quarter of 2024 demonstrated solid financial performance with growth across key segments. The company is navigating market dynamics and regulatory challenges while investing in strategic projects, such as the cobalt development programs and EO upgrade program. The management team is focused on long-term growth strategies and is preparing to share more insights at the upcoming Investor Day in New York City.
InvestingPro Insights
Sotera Health's recent financial performance aligns with key metrics provided by InvestingPro. The 8.5% revenue increase in Q3 2024 is consistent with InvestingPro data showing a 13.11% revenue growth over the last twelve months. The company’s strong financial position reflects a market capitalization of $4.37 billion and an EBITDA growth of 23.74% over the past year, contributing to a significant 36.58% price total return over six months. Investors should note that Sotera Health is trading at a P/E ratio of 63.3, but is described as trading at a low P/E ratio regarding near-term earnings growth, with a PEG ratio of 0.52.
For a comprehensive analysis, InvestingPro offers additional tips for a deeper understanding of the company's financial health and market position.
Full Transcript – Sotera Health Co (SHC) Q3 2024
Operator
Good morning, and welcome to the Sotera Health Third Quarter 2024 Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I would now like to turn the conference over to Vice President of Investor Relations and Treasurer, Jason Peterson. Jason, please go ahead.
Jason Peterson
Good morning, and thank you. Welcome to Sotera Health's Third Quarter 2024 Earnings Call. You can find today's press release and accompanying supplemental slides on the Investors section of our website at soterahealth.com. This webcast is being recorded, and a replay will be available.
Michael Petras
Good morning, everyone, and thank you for joining Sotera Health's Third Quarter 2024 Earnings Call… [continues with detailed financial information and outlook].
Comments (0)